If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
IPO today
Twelve Seas Investment Company (TWLVU)
Kensington Capital Acquisition (KCAC.U)
African Gold Acquisition (AGAC.U)
Fusion Acquisition II (FSNB.U)
Mcap Acquisition (MACQU)
Silverbox Engaged Merger I (SBEAU)
Ibere Pharmaceuticals (IBERU)
Freedom Acquisition I (FACT.U)
Arya Sciences Acquisition IV (ARYD)
Warrior Technologies Acquisition Company (WARR.U)
Austerlitz Acquisition Corporation II (ASZ.U)
Austerlitz Acquisition Corporation I (AUS.U)
Leo Holdings III Corp. (LIII.U)
Upcoming IPO
Property Solutions Acquisition II (PSAGU)
Nightdragon Acquisition (NDACU)
Roblox Corporation (RBLX)
Afc Gamma, Inc. (AFCG)
Roth Ch Acquisition III (ROCRU)
Oscar Health, Inc. (OSCR)
Innovage Holding Corp (INNV)
Priced IPO
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
Global Internet of People (SDH)
Baosheng Media Group Holdings (BAOS)
More companies

Adagene Inc. (ADAG)

Sector - Healthcare

Price chart

Return from IPO

Company News

IPO Profile

About company

They are a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Their platform is designed to generate therapeutic antibody candidates with unique functional epitopes and species cross-reactivity as highlighted by their immunotherapy pipeline. These features enable their novel drug discovery strategy to advance from lead identification through vigorous preclinical modeling to biomarker-guided mono- and combination immunotherapy development in clinical settings. They have pioneered a dynamic interface design to harness the conformational diversity of antibodies, which enlarges epitope sampling of a given drug target for differentiated therapeutic antibody development. They aim to push the boundaries of antibody discovery and engineering through the precise design, construction, and selection of antibody product candidates intractable to traditional antibody technology. Their most advanced NEObody product candidate, ADG106, is a fully human ligand-blocking agonistic anti-CD137 mAb currently being evaluated in Phase Ib clinical trials in the United States and China.
Peter (Peizhi) Luo Man Kin (Raymond) Tam
Employees Founded
198 2011


Address: 4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park Suzhou, Jiangsu Province, 215123 People's Republic of China

Telephone: +86-512-8777-3632

Web page:

IPO information

Expected Date 2/9/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7.4
Shares Revised (MM) 7.4
Expected offer amount (MM) $125
Realized offer amount(MM) $140.6

Financial Data (last reporting year)

Market Cap (MM) -
Revenues (MM) $0
Net Income (Loss) (MM) $-34.24


What do you think will happen with the ADAG share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Goldman Sachs

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Goldman Sachs/ Morgan Stanley/ Jefferies
China Renaissance

Sector: Healthcare

Tweets about $ADAG

Tweets volume:

RT volume:


Google Trends Stats